Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy

Completed · Phase 2 · Has a placebo group

Conditions studied: Spinal Muscular Atrophy

In brief

The primary objective of this proposal is to determine whether oral VPA is effective in treating SMA in adult patients.

Key facts

Study ID

NCT00481013

Run by

University of Utah

People needed

33

Starts

2007-07-01

Expected to finish

2010-11-01

Last updated by the study team

2016-12-06

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ambulatory adults with SMA 3 ages 18-60. The diagnosis of SMA must be documented by the homozygous deletion of both SMN1 genes on standard genetic tests for the disorder. Patients must be able to walk thirty feet without assistance (i.e. no canes, walkers).
• Interest in participating and the ability to meet the study requirements.
• Women of child bearing age are required to be on birth control or abstain while participating in the study.

You may not qualify if…

• Non-ambulatory type 3 adults and all type 2 adults.
• Patients with co-morbid conditions that preclude travel, testing or study medications.
• Patients who have participated in a treatment trial for SMA in the 3 months prior to this trial, or plan on enrolling in any other treatment trial during the duration of this trial.
• Patients who are, in the investigator's opinion, mentally or legally incapacitated from providing informed consent for the study, or are otherwise unable to meet study requirements or cooperate reliably with study procedures, especially strength testing.
• Patients with a need for non-invasive ventilatory support (e.g. BiPAP) for > 12 hours/day
• Transaminases, amylase or lipase > 3.0 x normal values, WBC < 3.0 or neutropenia < 1.0, platelet count < 100 K, or hematocrit < 30 persisting over a 30 day period
• Use of medications or supplements which interfere with VPA metabolism and increase the potential risks of the medications, or are hypothesized to have a beneficial effect in SMA animal models or human neuromuscular disorders within 3 months of study enrollment. These agents include riluzole, creatine, butyrate derivatives, growth hormone, anabolic steroids, daily albuterol use, anticonvulsants, or other HDAC inhibitors.
• Women who are pregnant or who intend to become pregnant while participating in the research study or who are breastfeeding.

Where it is running

• Ohio State University Medical Center, Dept. of Neurology — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.